Cargando…

Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023

IMPORTANCE: Several pharmacotherapies have been authorized to treat nonhospitalized persons with symptomatic COVID-19. Longitudinal information on the use of these therapies is needed. OBJECTIVE: To analyze trends and factors associated with prescription of outpatient COVID-19 pharmacotherapies with...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Lei, Streja, Elani, Li, Yuli, Rajeevan, Nallakkandi, Rowneki, Mazhgan, Berry, Kristin, Hynes, Denise M., Cunningham, Francesca, Huang, Grant D., Aslan, Mihaela, Ioannou, George N., Bajema, Kristina L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472184/
https://www.ncbi.nlm.nih.gov/pubmed/37651140
http://dx.doi.org/10.1001/jamanetworkopen.2023.31249
_version_ 1785100021443592192
author Yan, Lei
Streja, Elani
Li, Yuli
Rajeevan, Nallakkandi
Rowneki, Mazhgan
Berry, Kristin
Hynes, Denise M.
Cunningham, Francesca
Huang, Grant D.
Aslan, Mihaela
Ioannou, George N.
Bajema, Kristina L.
author_facet Yan, Lei
Streja, Elani
Li, Yuli
Rajeevan, Nallakkandi
Rowneki, Mazhgan
Berry, Kristin
Hynes, Denise M.
Cunningham, Francesca
Huang, Grant D.
Aslan, Mihaela
Ioannou, George N.
Bajema, Kristina L.
author_sort Yan, Lei
collection PubMed
description IMPORTANCE: Several pharmacotherapies have been authorized to treat nonhospitalized persons with symptomatic COVID-19. Longitudinal information on the use of these therapies is needed. OBJECTIVE: To analyze trends and factors associated with prescription of outpatient COVID-19 pharmacotherapies within the Veterans Health Administration (VHA). DESIGN, SETTING, AND PARTICIPANTS: This cohort study evaluated nonhospitalized veterans in VHA care who tested positive for SARS-CoV-2 from January 2022 through January 2023 using VHA and linked Community Care and Medicare databases. EXPOSURES: Demographic characteristics, underlying medical conditions, COVID-19 vaccination, and regional and local systems of care, including Veterans Integrated Services Networks (VISNs). MAIN OUTCOMES AND MEASURES: Monthly receipt of any COVID-19 pharmacotherapy (nirmatrelvir-ritonavir, molnupiravir, sotrovimab, or bebtelovimab) was described. Multivariable logistic regression was used to identify factors independently associated with receipt of any vs no COVID-19 pharmacotherapy. RESULTS: Among 285 710 veterans (median [IQR] age, 63.1 [49.9-73.7] years; 247 358 males [86.6%]; 28 444 Hispanic [10.0%]; 61 269 Black [21.4%] and 198 863 White [69.6%]) who tested positive for SARS-CoV-2 between January 2022 and January 2023, the proportion receiving any pharmacotherapy increased from 3285 of 102 343 veterans (3.2%) in January 2022 to 5180 of 21 688 veterans (23.9%) in August 2022. The proportion declined to 2194 of 10 551 veterans (20.8%) by January 2023. Across VISNs, the range in proportion of patients who tested positive who received nirmatrelvir-ritonavir or molnupiravir during January 2023 was 41 of 692 veterans (5.9%) to 106 of 494 veterans (21.4%) and 2.1% to 120 of 1074 veterans (11.1%), respectively. Veterans receiving any treatment were more likely to be older (adjusted odds ratio [aOR] for ages 65-74 vs 50-64 years, 1.18; 95% CI, 1.14-1.22; aOR for ages ≥75 vs 50-64 years, 1.19; 95% CI, 1.15-1.23) and have a higher Charlson Comorbidity Index score (aOR for CCI ≥6 vs 0, 1.52; 95% CI, 1.44-1.59). Compared with White veterans, Black veterans (aOR, 1.06; 95% CI, 1.02-1.09) were more likely to receive treatment, and compared with non-Hispanic veterans, Hispanic veterans (aOR 1.06; 95% CI, 1.01-1.11) were more likely to receive treatment. CONCLUSIONS AND RELEVANCE: This study found that prescription of outpatient COVID-19 pharmacotherapies in the VHA peaked in August 2022 and declined thereafter. There were large regional differences in patterns of nirmatrelvir-ritonavir and molnupiravir use.
format Online
Article
Text
id pubmed-10472184
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-104721842023-09-02 Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023 Yan, Lei Streja, Elani Li, Yuli Rajeevan, Nallakkandi Rowneki, Mazhgan Berry, Kristin Hynes, Denise M. Cunningham, Francesca Huang, Grant D. Aslan, Mihaela Ioannou, George N. Bajema, Kristina L. JAMA Netw Open Original Investigation IMPORTANCE: Several pharmacotherapies have been authorized to treat nonhospitalized persons with symptomatic COVID-19. Longitudinal information on the use of these therapies is needed. OBJECTIVE: To analyze trends and factors associated with prescription of outpatient COVID-19 pharmacotherapies within the Veterans Health Administration (VHA). DESIGN, SETTING, AND PARTICIPANTS: This cohort study evaluated nonhospitalized veterans in VHA care who tested positive for SARS-CoV-2 from January 2022 through January 2023 using VHA and linked Community Care and Medicare databases. EXPOSURES: Demographic characteristics, underlying medical conditions, COVID-19 vaccination, and regional and local systems of care, including Veterans Integrated Services Networks (VISNs). MAIN OUTCOMES AND MEASURES: Monthly receipt of any COVID-19 pharmacotherapy (nirmatrelvir-ritonavir, molnupiravir, sotrovimab, or bebtelovimab) was described. Multivariable logistic regression was used to identify factors independently associated with receipt of any vs no COVID-19 pharmacotherapy. RESULTS: Among 285 710 veterans (median [IQR] age, 63.1 [49.9-73.7] years; 247 358 males [86.6%]; 28 444 Hispanic [10.0%]; 61 269 Black [21.4%] and 198 863 White [69.6%]) who tested positive for SARS-CoV-2 between January 2022 and January 2023, the proportion receiving any pharmacotherapy increased from 3285 of 102 343 veterans (3.2%) in January 2022 to 5180 of 21 688 veterans (23.9%) in August 2022. The proportion declined to 2194 of 10 551 veterans (20.8%) by January 2023. Across VISNs, the range in proportion of patients who tested positive who received nirmatrelvir-ritonavir or molnupiravir during January 2023 was 41 of 692 veterans (5.9%) to 106 of 494 veterans (21.4%) and 2.1% to 120 of 1074 veterans (11.1%), respectively. Veterans receiving any treatment were more likely to be older (adjusted odds ratio [aOR] for ages 65-74 vs 50-64 years, 1.18; 95% CI, 1.14-1.22; aOR for ages ≥75 vs 50-64 years, 1.19; 95% CI, 1.15-1.23) and have a higher Charlson Comorbidity Index score (aOR for CCI ≥6 vs 0, 1.52; 95% CI, 1.44-1.59). Compared with White veterans, Black veterans (aOR, 1.06; 95% CI, 1.02-1.09) were more likely to receive treatment, and compared with non-Hispanic veterans, Hispanic veterans (aOR 1.06; 95% CI, 1.01-1.11) were more likely to receive treatment. CONCLUSIONS AND RELEVANCE: This study found that prescription of outpatient COVID-19 pharmacotherapies in the VHA peaked in August 2022 and declined thereafter. There were large regional differences in patterns of nirmatrelvir-ritonavir and molnupiravir use. American Medical Association 2023-08-31 /pmc/articles/PMC10472184/ /pubmed/37651140 http://dx.doi.org/10.1001/jamanetworkopen.2023.31249 Text en Copyright 2023 Yan L et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Yan, Lei
Streja, Elani
Li, Yuli
Rajeevan, Nallakkandi
Rowneki, Mazhgan
Berry, Kristin
Hynes, Denise M.
Cunningham, Francesca
Huang, Grant D.
Aslan, Mihaela
Ioannou, George N.
Bajema, Kristina L.
Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023
title Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023
title_full Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023
title_fullStr Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023
title_full_unstemmed Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023
title_short Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023
title_sort anti–sars-cov-2 pharmacotherapies among nonhospitalized us veterans, january 2022 to january 2023
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472184/
https://www.ncbi.nlm.nih.gov/pubmed/37651140
http://dx.doi.org/10.1001/jamanetworkopen.2023.31249
work_keys_str_mv AT yanlei antisarscov2pharmacotherapiesamongnonhospitalizedusveteransjanuary2022tojanuary2023
AT strejaelani antisarscov2pharmacotherapiesamongnonhospitalizedusveteransjanuary2022tojanuary2023
AT liyuli antisarscov2pharmacotherapiesamongnonhospitalizedusveteransjanuary2022tojanuary2023
AT rajeevannallakkandi antisarscov2pharmacotherapiesamongnonhospitalizedusveteransjanuary2022tojanuary2023
AT rownekimazhgan antisarscov2pharmacotherapiesamongnonhospitalizedusveteransjanuary2022tojanuary2023
AT berrykristin antisarscov2pharmacotherapiesamongnonhospitalizedusveteransjanuary2022tojanuary2023
AT hynesdenisem antisarscov2pharmacotherapiesamongnonhospitalizedusveteransjanuary2022tojanuary2023
AT cunninghamfrancesca antisarscov2pharmacotherapiesamongnonhospitalizedusveteransjanuary2022tojanuary2023
AT huanggrantd antisarscov2pharmacotherapiesamongnonhospitalizedusveteransjanuary2022tojanuary2023
AT aslanmihaela antisarscov2pharmacotherapiesamongnonhospitalizedusveteransjanuary2022tojanuary2023
AT ioannougeorgen antisarscov2pharmacotherapiesamongnonhospitalizedusveteransjanuary2022tojanuary2023
AT bajemakristinal antisarscov2pharmacotherapiesamongnonhospitalizedusveteransjanuary2022tojanuary2023